

Anton I Rosenbaum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8109828/publications.pdf>

Version: 2024-02-01

19
papers

1,014
citations

623188

14
h-index

752256

20
g-index

21
all docs

21
docs citations

21
times ranked

1448
citing authors

#	ARTICLE	IF	CITATIONS
1	Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 5477-5482.	3.3	229
2	Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches. <i>Journal of Neurochemistry</i> , 2011, 116, 789-795.	2.1	205
3	The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. <i>Science Translational Medicine</i> , 2022, 14, eabl8124.	5.8	143
4	Thiadiazole Carbamates: Potent Inhibitors of Lysosomal Acid Lipase and Potential Niemann-Pick Type C Disease Therapeutics. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 5281-5289.	2.9	75
5	Chemical screen to reduce sterol accumulation in Niemann-Pick C disease cells identifies novel lysosomal acid lipase inhibitors. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009, 1791, 1155-1165.	1.2	50
6	Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2. <i>Antibodies</i> , 2019, 8, 11.	1.2	40
7	First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1442-1453.	1.9	38
8	Investigation of N-Aryl-3-alkylidenepyrrolinones as Potential Niemann-Pick Type C Disease Therapeutics. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6494-6498.	2.9	29
9	Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease. <i>Scientific Reports</i> , 2021, 11, 22521.	1.6	27
10	ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates. <i>Antibodies</i> , 2018, 7, 41.	1.2	24
11	Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. <i>Clinical Cancer Research</i> , 2021, 27, 3602-3609.	3.2	20
12	Characterization of Antibody-Drug Conjugate Pharmacokinetics and in Vivo Biotransformation Using Quantitative Intact LC-HRMS and Surrogate Analyte LC-MRM. <i>Analytical Chemistry</i> , 2021, 93, 6135-6144.	3.2	17
13	Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trial. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	16
14	Multifaceted Bioanalytical Methods for the Comprehensive Pharmacokinetic and Catabolic Assessment of MEDI3726, an Anti-Prostate-Specific Membrane Antigen Pyrrolbenzodiazepine Antibody-Drug Conjugate. <i>Analytical Chemistry</i> , 2020, 92, 11135-11144.	3.2	15
15	Targeted oral peptide delivery using multi-unit particulates: Drug and permeation enhancer layering approach. <i>Journal of Controlled Release</i> , 2021, 338, 784-791.	4.8	14
16	2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A) Recommendations on Endogenous Compounds, Small Molecules.) Tj ETQq0,0 0 rgBT, /Overlock		14
17	Bioanalytical Methods and Strategic Perspectives Addressing the Rising Complexity of Novel Bioconjugates and Delivery Routes for Biotherapeutics. <i>BioDrugs</i> , 2022, 36, 181-196.	2.2	8
18	LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 3005-3014.	1.1	6

#	ARTICLE	IF	CITATIONS
19	Differences in levels of phosphatidylinositols in healthy and stable Coronary Artery Disease subjects revealed by HILIC-MRM method with SERRF normalization. PLoS ONE, 2021, 16, e0252426.	1.1	3